Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation

Blood

Volumn 101, Issue 12, 2003, Pages 4937-4943

  Sexl, Veronika ^a   Kovacic, Boris ^b   Piekorz, Roland ^b   Moriggl, Richard ^b   Stoiber, Dagmar ^b   Hoffmeyer, Angelika ^b   Liebminger, Rita ^b   Kudlacek, Oliver ^b   Weisz, Eva ^b   Rothammer, Kristen ^b   Ihle, James N ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; JANUS KINASE; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER GRAFT; CANCER INHIBITION; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; ENZYME DEFICIENCY; GENE FUNCTION; HEMATOLOGIC MALIGNANCY; IMMUNE DEFICIENCY; IN VITRO STUDY; MALIGNANT TRANSFORMATION; MOUSE; MOUSE STRAIN; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE ABELSON; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STRAIN DIFFERENCE; TUMOR GROWTH; WILD TYPE;

EID: 10744222975     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2001-11-0142     Document Type: Article

References (43)

1. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002;109(suppl):S121-S131.
2. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13:211-217.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303.
4. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474-2488.
5. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000;79:67-73.
6. Gao B, Shen X, Kunos G, et al. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. FEBS Lett. 2001;488:179-184.
7. Campbell CL, Jiang Z, Savarese DM, Savarese TM. Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol. 2001;158:25-32.
8. Frank DA, Mahajan S, Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997;100:3140-3148.
9. Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076-2083.
10. Coffer PJ, Koenderman L, de Groot RP. The role of STATs in myeloid differentiation and leukemia. Oncogene. 2000;19:2511-2522.
11. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19:2496-2504.
12. Gouilleux-Gruart V, Debierre-Grockiego F, Gouilleux F, et al. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma. 1997;28:83-88.
13. Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 1996;13:247-254.
14. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720-4728.
15. Schwaller J, Parganas E, Wang D, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000;6:693-704.
16. Abelson HT, Rabstein LS. Influence of prednisolone on Moloney leukemogenic virus in BALB-c mice. Cancer Res. 1970;30:2208-2212.
17. Witte ON. Functions of the abl encogene. Cancer Surv. 1986;5:183-197.
18. Rosenberg N, Witte ON. The viral and cellular forms of the Abelson (abl) oncogene. Adv Virus Res. 1988;35:39-81.
19. Palumbo GJ, Ozanne BW, Kettman JR. Multistage progression of Abelson virus-infected murine pre-B-cells to the tumorgenic state. Cancer Res. 1990;50:1917-1923.
20. Cong F, Zou X, Hinrichs K, Calame K, Goff SP. Inhibition of v-Abl transformation by p53 and p19ARF. Oncogene. 1999;18:7731-7739.
21. Unnikrishnan I, RadfarA, Jenab-Wocott J, Rosenberg N. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol Cell Biol. 1999;19:4825-4831.
22. Danial NN, Pernis A, Rothman PB. Jak-STAT sig STAT-signaling induced by the v-abl oncogene. Science. 1995;269:1875-1877.
23. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood. 2000;96:2277-2283.
24. Danial NN, Losman JA, Lu T, et al. Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation. Mol Cell Biol. 1998;18:6795-6804.
25. Zhang Y, Turkson J, Carter-Su C, et al. Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem. 2000;275:24935-24944.
26. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and non-redundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373-383.
27. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993;259:1739-1742.
28. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature. 1983;301:527-530.
29. Moriggl R, Berchtold S, Friedrich K, et al. Comparison of the transactivation domains of Stat5 and Stat6 in lymphoid cells and mammary epithelial cells. Mol Cell Biol. 1997;17:3663-3678.
30. Moriggl R, Topham DJ, Teglund S, et al. Stat5 is required for IL-2 induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249-259.
31. Farrar MA, Schreiber RD. The molecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol. 1993;11:571-611.
32. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol. 1997;15:749-795.
33. Grawunder U, Melchers F, Rolink A. Interferon-gamma rrests proliferation and causes apoptosis in stromal cell/interleukin-7-dependent normal murine pre-B cell lines and clones in vitro, but does not induce differentiation to surface immunoglobulin-positive B cells. Eur J Immunol. 1993;23:544-551.
34. Young HA, Klinman DM, Reynolds DA, et al. Bone marrow and thymus expression of interferon-gamma results in severe B-cell lineage reduction, T-cell lineage alterations, and hematopoietic progenitor deficiencies. Blood. 1997;89:583-595.
35. + cells produce IFN-γ in mice infected with Borrelia burgdorferi. Eur J Immunol. 2001;31:3460-3468.
36. Tang H, Matthes, T, Carballido-Perrig N, Zubler RH, Kindler V. Differential induction of T cell cytokine mRNA in Epstein-Barr virus transformed B cell clones: constitutive and inducible expression of interleukin-4 mRNA. Eur J Immunol. 1993;23:899-903.
37. Pang Y, Norihisa Y, Benjamin D, Kantor RR, Young HA. Interferon-gamma gene expression in human B cell lines: induction by interleukin-2, protein kinase C activators, and possible effect of hypermethylationon gene regulation. Blood. 1992;80:724-732.
38. Jelinek DF, Braaten JK. Role of IL-12 in human B lymphocyte proliferation and differentiation. J Immunol. 1995;154:1606-1613.
39. Park C, Li S, Cha E, Schindler C. Immune response in Stat2 knockout mice. Immunity. 2000;13:795-804.
40. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19:2468-2473.
41. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U.S.A. 1998;95:7556-7561.
42. Shankaran V, Ikeda H, Bruce AT, et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107-1111.
43. Biethahn S, Alves F, Wilde S, Hiddemann W, Spiekermann K. Expression of granulocyte colony-stimulating factor- and granulocyte-macrophage colony-stimulating factor-associated signal transduction proteins of the JAK/STAT pathway in normal granulopoiesis and in blast cells of acute myelogenous leukemia. Exp Hematol. 1999;27:885-894.